Sage Therapeutics faced the wrath of finicky investors on March 23 as its shares dropped more 20% in early morning trading in response to a scathing report from a hedge fund that has a short positions on the stock. The overblown reaction is a good indicator of market climate.
The biotech's shares dipped precipitously in morning trading, but recovered slightly as the trading day went on. Shares were down 14.63%, or $4.89, to trade near $28.56 around the close...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?